Technical Analysis for ZLAB - Zai Lab Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
34.04 | -0.23% | -0.08 |
ZLAB closed down 0.23 percent on Friday, October 18, 2019, on 52 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical ZLAB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | -0.23% | |
| Pocket Pivot | Bullish Swing Setup | -0.23% | |
| Stochastic Reached Overbought | Strength | -0.23% | |
| Overbought Stochastic | Strength | -0.23% | |
| Fell Below 50 DMA | Bearish | 2.38% | |
| 50 DMA Support | Bullish | 0.83% | |
| Doji - Bearish? | Reversal | 0.83% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/03/2019
- Sector: Healthcare
- Industry: Biotechnology
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Biopharmaceutical Pharmaceutical Industry Natural Sciences Medication
Biopharmaceutical Pharmaceutical Industry Natural Sciences Medication
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ZLAB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 38.44 |
| 52 Week Low | 15.15 |
| Average Volume | 180,168 |
| 200-Day Moving Average | 30.6655 |
| 50-Day Moving Average | 33.5636 |
| 20-Day Moving Average | 32.7565 |
| 10-Day Moving Average | 32.827 |
| Average True Range | 1.3933 |
| ADX | 15.96 |
| +DI | 18.4179 |
| -DI | 14.829 |
| Chandelier Exit (Long, 3 ATRs ) | 31.1401 |
| Chandelier Exit (Short, 3 ATRs ) | 34.8999 |
| Upper Bollinger Band | 34.6654 |
| Lower Bollinger Band | 30.8476 |
| Percent B (%b) | 0.84 |
| BandWidth | 11.655091 |
| MACD Line | -0.0078 |
| MACD Signal Line | -0.2728 |
| MACD Histogram | 0.2651 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.67 Billion |
| Num Shares | 49.1 Million |
| EPS | -4.94 |
| Price-to-Earnings (P/E) Ratio | -6.89 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 35.71 | ||||
| Resistance 3 (R3) | 35.66 | 35.07 | 35.43 | ||
| Resistance 2 (R2) | 35.07 | 34.64 | 35.09 | 35.33 | |
| Resistance 1 (R1) | 34.55 | 34.38 | 34.26 | 34.60 | 35.24 |
| Pivot Point | 33.96 | 33.96 | 33.81 | 33.98 | 33.96 |
| Support 1 (S1) | 33.44 | 33.53 | 33.15 | 33.49 | 32.84 |
| Support 2 (S2) | 32.85 | 33.27 | 32.87 | 32.75 | |
| Support 3 (S3) | 32.33 | 32.85 | 32.65 | ||
| Support 4 (S4) | 32.38 |
